Compounds > lutetium
Page last updated: 2024-08-22

lutetium and lutetium lu 177 dotatate

lutetium has been researched along with lutetium lu 177 dotatate in 53 studies

Research

Studies (53)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (22.64)29.6817
2010's34 (64.15)24.3611
2020's7 (13.21)2.80

Authors

AuthorsStudies
Bakker, WH; Bugaj, JL; de Jong, M; Erion, JL; Konijnenberg, MW; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Schmidt, MA; Srinivasan, A1
Bernard, BF; Breeman, WA; de Jong, M; Erion, JL; Krenning, EP; van der Wansem, K; van Gameren, A; Visser, TJ1
Ahlman, H; Bernhardt, P; Forssel-Aronsson, E; Kölby, L; Nilsson, O; Schmitt, A; Schmitt, J1
Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Valkema, R1
de Jong, M; Esser, JP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R1
Banerjee, S; Chakraborty, S; Das, T; Venkatesh, M1
Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Kölby, L; Nilsson, O; Oddstig, J1
de Herder, WW; de Keizer, B; Feelders, RA; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M1
Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Johanson, V; Kölby, L; Nilsson, O; Schmitt, A; Stridsberg, M; Swärd, C1
Bernard, BF; Boerman, OC; Breeman, WA; de Blois, E; de Jong, M; Forrer, F; Gotthardt, M; Hoppin, J; Krenning, EP; Rolleman, EJ1
Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M1
Agazzi, A; Aricò, D; Bodei, L; De Cicco, C; De Simone, M; Pacifici, M; Paganelli, G; Quarna, J; Sansovini, M; Sierra, ML1
Garkavij, M; Ljungberg, M; Nickel, M; Ohlsson, T; Sjögreen-Gleisner, K; Strand, SE; Tennvall, J; Wingårdh, K1
Banerjee, S; Chakraborty, S; Das, T; Kallur, KG; Venkatesh, M1
Barkhausen, C; Cohrs, S; Fischer, E; Grünberg, J; Hohn, A; Köster, U; Lehenberger, S; Schibli, R; Türler, A; Zhernosekov, K1
Balkin, ER; Jia, F; Lewis, MR; Miller, WH1
Asti, M; Cutler, CS; Farioli, D; Guidotti, C; Iori, M; Mayer, P; Salvo, D; Tegoni, M; Versari, A1
de Herder, WW; Kam, BL; Khan, S; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; van Vliet, EI1
Briel, M; Brunner, P; Koller, MT; Mäcke, HR; Marincek, N; Müller-Brand, J; Ng, QK; Rochlitz, C; Romer, A; Schindler, C; Villard, L; Walter, MA1
Cwikla, J; Gut, P; Handkiewicz-Junak, D; Hubalewska-Dydejczyk, A; Jakuciński, M; Kamiński, G; Kowalska, A; Królicki, L; Kunikowska, J; Lukiewicz, A; Mikolajczak, R; Pawlak, D; Sowa-Staszczak, A; Szaluś, N1
Hubalewska-Dydejczyk, A; Sowa-Staszczak, A; Tomaszuk, M1
Baum, RP; Kulkarni, HR; Müller, D; Prasad, V; Schuchardt, C; Zachert, C1
Kairemo, K; Kangasmäki, A1
Baum, RP; Kulkarni, HR; Schuchardt, C1
Baum, RP; Kulkarni, HR; Prasad, V; Schuchardt, C1
Banks, M; Cuthbertson, DJ; Daousi, C; Dobson, R; Hsuan, J; Poston, GP; Terlizzo, M; Vinjamuri, S; Wieshmann, H1
Aldridge, M; Bomanji, J; Fersht, N; Maclean, J; Short, S1
Banerjee, S; Das, T; Kamaleshwaran, KK; Sarma, HD; Shinto, A1
Del Pozzo, L; Fani, M; Fischer, R; Kaul, F; Krebs, S; Maecke, HR; Reubi, JC; Rivier, JE; Weber, WA; Wild, D1
Banerjee, S; Das, T1
Dash, A; Korde, A; Lohar, S; Mukherjee, A; Samuel, G; Sarma, HD1
Konijnenberg, MW1
Breeman, WA; Chan, HS; de Blois, E; de Zanger, RM1
Brolin, G; Gleisner, KS; Larsson, E; Mjekiqi, E; Östlund, K; Sundlöv, A; Tennvall, J1
Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G1
Bergsma, H; de Herder, WW; Franssen, GJ; Kam, BL; Konijnenberg, MW; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; van Eijck, CH1
Adjogatse, D; Black, JR; Pinato, DJ; Ramaswami, R; Sharma, R; Tan, TM1
Cives, M; Soares, HP; Strosberg, J1
Ballinger, JR1
Jones, IW; Matthews, LF1
Buxbaum, S; Fink, K; Maffey-Steffan, J; Mair, C; Nilica, B; Scarpa, L; Virgolini, IJ; Warwitz, B1
Delpassand, ES; Hendifar, AE; Kittleson, MM; Tuli, R1
Blažević, A; Brabander, T; de Herder, WW; Feelders, RA; Hofland, J; Kam, BLR; Teunissen, JJM; Zandee, WT1
Courbon, F; Dierickx, L; Vija, L1
Brabander, T; Hofland, J; Nonnekens, J1
Baum, RP; Liu, C; Liu, T; Yang, Z; Zhang, J1
Barentsz, MW; Braat, AJAT; Ebbers, SC; Lam, MGEH; Moelker, A; Stokkel, MPM1
Chitwood, H; Myers, A1
Martins, H; Moreira, AP; Silva, R; Soeiro, P1
Cullinane, C; Eu, P; Hicks, RJ; Kirby, L; Rogers, BE; Tothill, RW; Waldeck, K1
Baum, RP; Hommann, M; Hörsch, D; Kaemmerer, D; Kulkarni, HR; Sehner, S; Twrznik, M1
de Vries-Huizing, DMV; de Wit-van der Veen, BJ; Geluk-Jonker, MM; Hendrikx, JJMA; Sinaasappel, M; Stokkel, MPM; Tesselaar, MET; Versleijen, MWJ; Walraven, I1
Barakat, A; Deshayes, E; Khier, S; Kotzki, PO; Santoro, L; Vivien, M1

Reviews

5 review(s) available for lutetium and lutetium lu 177 dotatate

ArticleYear
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
    Best practice & research. Clinical gastroenterology, 2005, Volume: 19, Issue:4

    Topics: Animals; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Patient Selection; Pentetic Acid; Peptides, Cyclic; Quality of Life; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Somatostatin; Treatment Outcome; Yttrium Radioisotopes

2005
Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39 Suppl 1

    Topics: Disease-Free Survival; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Somatostatin

2012
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Current opinion in oncology, 2016, Volume: 28, Issue:4

    Topics: Clinical Trials, Phase III as Topic; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Somatostatin; Stomach Neoplasms

2016
Theranostic radiopharmaceuticals: established agents in current use.
    The British journal of radiology, 2018, Volume: 91, Issue:1091

    Topics: 3-Iodobenzylguanidine; Antigens, CD20; Bone Neoplasms; Dipeptides; Diphosphonates; Drug Approval; Forecasting; Heterocyclic Compounds, 1-Ring; Hodgkin Disease; Humans; Iodine Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Prostate-Specific Antigen; Radiopharmaceuticals; Somatostatin; Theranostic Nanomedicine; Thyroid Diseases

2018
The next generation of peptide receptor radionuclide therapy.
    Endocrine-related cancer, 2019, Volume: 26, Issue:8

    Topics: Animals; HSP90 Heat-Shock Proteins; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Treatment Outcome

2019

Trials

1 trial(s) available for lutetium and lutetium lu 177 dotatate

ArticleYear
Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
    Trials, 2020, Feb-05, Volume: 21, Issue:1

    Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Coordination Complexes; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver; Liver Neoplasms; Lutetium; Male; Multicenter Studies as Topic; Neuroendocrine Tumors; Octreotide; Radioisotopes; Randomized Controlled Trials as Topic; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome

2020

Other Studies

47 other study(ies) available for lutetium and lutetium lu 177 dotatate

ArticleYear
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
    European journal of nuclear medicine, 2001, Volume: 28, Issue:9

    Topics: Adolescent; Adult; Aged; Female; Humans; Indium Radioisotopes; Lutetium; Male; Middle Aged; Neoplasms; Octreotide; Organometallic Compounds; Radiation Dosage; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin

2001
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:2

    Topics: Animals; Bone Marrow; Femur; Heterocyclic Compounds, 1-Ring; Injections, Intravenous; Kidney; Lutetium; Male; Octreotide; Organ Specificity; Organometallic Compounds; Pentetic Acid; Radiation-Protective Agents; Radioisotopes; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution

2003
Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
    Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:4

    Topics: Algorithms; Animals; Carcinoma, Small Cell; Cell Line, Tumor; Humans; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radiotherapy Dosage; Somatostatin; Time Factors; Tissue Distribution

2003
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46 Suppl 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Humans; Lutetium; Male; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Somatostatin; Survival Analysis; Treatment Outcome; Yttrium

2005
On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2007, Volume: 65, Issue:3

    Topics: Drug Stability; Heterocyclic Compounds, 1-Ring; Isotope Labeling; Lutetium; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals

2007
Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice.
    Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:5

    Topics: Animals; Carcinoid Tumor; Cell Line, Tumor; Dose-Response Relationship, Radiation; Humans; Indium Radioisotopes; Injections, Intravenous; Lutetium; Mice; Mice, Nude; Octreotide; Organometallic Compounds; Radioisotopes; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2007
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Endocrine System Diseases; Gastrointestinal Neoplasms; Humans; Lutetium; Middle Aged; Neuroectodermal Tumors, Primitive; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Retrospective Studies

2008
Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
    Cancer biotherapy & radiopharmaceuticals, 2008, Volume: 23, Issue:1

    Topics: Animals; Carcinoid Tumor; Chromogranin A; Humans; Intestinal Neoplasms; Lutetium; Mice; Mice, Nude; Octreotide; Organometallic Compounds; Radiotherapy Dosage; Receptors, Somatostatin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008
Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.
    Nuklearmedizin. Nuclear medicine, 2008, Volume: 47, Issue:3

    Topics: Animals; Biological Transport; Drug Hypersensitivity; Humans; Kidney; Lutetium; Lysine; Octreotide; Organometallic Compounds; Polygeline; Radioisotopes; Rats; Tomography, Emission-Computed, Single-Photon

2008
[Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Ugeskrift for laeger, 2009, Mar-23, Volume: 171, Issue:13

    Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes

2009
Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:6

    Topics: Adult; Aged; B-Lymphocytes; Colonic Neoplasms; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Lung Neoplasms; Lutetium; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Yttrium Radioisotopes

2009
177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
    Cancer, 2010, Feb-15, Volume: 116, Issue:4 Suppl

    Topics: Forecasting; Humans; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage

2010
Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.
    Cancer biotherapy & radiopharmaceuticals, 2011, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Drug Design; Humans; India; Lutetium; Nuclear Medicine; Octreotide; Organometallic Compounds; Quality Control; Radiopharmaceuticals; Receptors, Somatostatin; Reproducibility of Results; Somatostatin

2011
The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.
    Nuclear medicine and biology, 2011, Volume: 38, Issue:6

    Topics: Beta Particles; Electrons; Humans; Lutetium; Nuclear Reactors; Octreotide; Organometallic Compounds; Radiochemistry; Radioisotopes; Radiotherapy; Terbium

2011
In vitro evaluation of targeted antisense 177Lu radiotherapy.
    Anticancer research, 2011, Volume: 31, Issue:10

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Lutetium; Molecular Targeted Therapy; Octreotide; Organometallic Compounds; Peptide Nucleic Acids; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Radioisotopes; Radiometry; Radiotherapy

2011
Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions.
    Nuclear medicine and biology, 2012, Volume: 39, Issue:4

    Topics: Cations; Isotope Labeling; Lutetium; Octreotide; Organometallic Compounds; Radiochemistry; Reference Standards; Yttrium Radioisotopes

2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioisotopes; Somatostatin; Yttrium Radioisotopes

2012
Polish experience in Peptide receptor radionuclide therapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes

2013
PRRT as neoadjuvant treatment in NET.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Humans; Lutetium; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Receptors, Somatostatin

2013
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Adult; Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Whole-Body Counting

2013
4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Four-Dimensional Computed Tomography; Humans; Lutetium; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Receptors, Somatostatin; Software; Tomography, X-Ray Computed

2013
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin

2013
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Blood Cells; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiation Dosage; Radiopharmaceuticals; Receptors, Somatostatin; Spleen

2013
Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-10, Volume: 31, Issue:17

    Topics: Aged; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Orbital Neoplasms; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals

2013
Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.
    Pituitary, 2014, Volume: 17, Issue:6

    Topics: Adult; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lutetium; Male; Middle Aged; Octreotide; Organometallic Compounds; Pituitary Neoplasms; Positron-Emission Tomography; Prolactinoma; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2014
Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy.
    Current radiopharmaceuticals, 2014, Volume: 7, Issue:1

    Topics: Adult; Animals; Chromatography, High Pressure Liquid; Freeze Drying; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Quality Control; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Whole Body Imaging

2014
Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:8

    Topics: Adult; Aged; Amino Acid Sequence; Feasibility Studies; Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Oligopeptides; Organometallic Compounds; Pilot Projects; Radioisotopes; Radiometry; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome

2014
Formulation of patient dose of ¹⁷⁷Lu-DOTA-TATE in hospital radiopharmacy in India: preparation using in situ methodology vis-a-vis freeze-dried kit.
    Cancer biotherapy & radiopharmaceuticals, 2014, Volume: 29, Issue:7

    Topics: Chemistry, Pharmaceutical; Freeze Drying; Hospitals; Humans; India; Lutetium; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals

2014
Single vial kit formulation of DOTATATE for preparation of (177) Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy.
    Journal of labelled compounds & radiopharmaceuticals, 2015, Volume: 58, Issue:4

    Topics: Contrast Media; Isotope Labeling; Lutetium; Materials Testing; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Reagent Kits, Diagnostic

2015
Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry.
    Current radiopharmaceuticals, 2015, Volume: 8, Issue:2

    Topics: Half-Life; Humans; Lutetium; Octreotide; Organometallic Compounds; Radioisotopes; Radiometry; Radiopharmaceuticals

2015
Alternative method to determine Specific Activity of (177)Lu by HPLC.
    Current radiopharmaceuticals, 2015, Volume: 8, Issue:2

    Topics: Chromatography, High Pressure Liquid; Heterocyclic Compounds, 1-Ring; Lutetium; Octreotide; Organometallic Compounds; Peptides; Radiochemistry; Radioisotopes; Receptors, Peptide

2015
Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:7

    Topics: Female; Gamma Cameras; Gamma Rays; Humans; Kidney; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Phantoms, Imaging; Radioisotopes; Radiometry; Receptors, Peptide; Spectrophotometry; Spleen; Time Factors

2015
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:3

    Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome

2016
Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:3

    Topics: Aged; Bone Marrow; Female; Humans; Iodine; Lutetium; Male; Middle Aged; Netherlands; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prognosis; Prospective Studies; Radiation Injuries; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Peptide; Risk Factors; Treatment Outcome

2016
Peptide receptor radionuclide therapy for metastatic paragangliomas.
    Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:5

    Topics: Adolescent; Adult; Female; Humans; Kaplan-Meier Estimate; Lutetium; Male; Middle Aged; Octreotide; Organometallic Compounds; Paraganglioma; Radioisotopes; Radiotherapy; Treatment Outcome

2016
The effect of kidney volume estimation on dosimetry in lutetium-177 DOTATATE therapy.
    Nuclear medicine communications, 2018, Volume: 39, Issue:6

    Topics: Humans; Kidney; Lutetium; Octreotide; Organ Size; Organometallic Compounds; Radioisotopes; Radiometry; Tomography, X-Ray Computed

2018
Radiation exposure after
    Annals of nuclear medicine, 2018, Volume: 32, Issue:7

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Neoplasms; Octreotide; Organometallic Compounds; Organs at Risk; Prostate-Specific Antigen; Radiometry; Radiotherapy Dosage; Salivary Glands; Single Photon Emission Computed Tomography Computed Tomography; Whole Body Imaging

2018
Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.
    Pancreas, 2018, Volume: 47, Issue:8

    Topics: Cardiotoxicity; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide

2018
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
    The Journal of clinical endocrinology and metabolism, 2019, 04-01, Volume: 104, Issue:4

    Topics: Adult; Aged; Coordination Complexes; Female; Gastrins; Glucagon; Humans; Insulin; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Quality of Life; Radiation Dosage; Radioisotopes; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Vasoactive Intestinal Peptide

2019
Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
    Annales d'endocrinologie, 2019, Volume: 80, Issue:3

    Topics: Clinical Trials, Phase III as Topic; France; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Precision Medicine; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Receptors, Somatostatin

2019
Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:11

    Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Peptide; Treatment Outcome

2019
Peptide Receptor Radionuclide Therapy: An Emerging Treatment for Gastrointestinal Neuroendocrine Tumors.
    Clinical journal of oncology nursing, 2020, 04-01, Volume: 24, Issue:2

    Topics: Adult; Coordination Complexes; Female; Gastrointestinal Neoplasms; Humans; Lutetium; Neuroendocrine Tumors; Nurses; Octreotide; Receptors, Peptide

2020
Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.
    BMJ case reports, 2020, Mar-31, Volume: 13, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Humans; Liver Neoplasms; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Receptors, Peptide; Remission Induction

2020
Enhancing the anti-tumour activity of
    Scientific reports, 2020, 06-23, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Lutetium; Mice; Mice, Inbred BALB C; Mice, Nude; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin

2020
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.
    Annals of surgery, 2021, 07-01, Volume: 274, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes

2021
Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course.
    PloS one, 2021, Volume: 16, Issue:11

    Topics: Aged; Female; Gallium Radioisotopes; Hemolytic Agents; Humans; Leukocytes; Lutetium; Male; Middle Aged; Netherlands; Neuroendocrine Tumors; Neutrophils; Octreotide; Organometallic Compounds; Platelet Count; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies

2021
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera
    European journal of drug metabolism and pharmacokinetics, 2023, Volume: 48, Issue:4

    Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2023